Analytical Data
-
Gene name
TARDBP
- Application
-
Alternative Names
Short name: TDP-43
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13148
-
Expression Region
25-181aa
-
Molecular Weight
21.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TARDBP, or TAR DNA-binding protein, is a crucial protein involved in various cellular processes, including RNA metabolism, gene regulation, and neuroprotection. Its significance has gained prominence due to its link with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Mutations in the TARDBP gene can lead to the formation of toxic aggregates in motor neurons, contributing to disease pathology. Research into TARDBP has focused on understanding its structure and function, as well as the impact of its pathological variants. The study of recombinant TARDBP proteins has become essential in elucidating the mechanisms by which these mutations disrupt normal cellular functions and lead to neurodegeneration. Moreover, the recombination technology enables scientists to produce purified TARDBP protein, facilitating biochemical assays, structural analysis, and investigations into interaction with RNA and other proteins. By studying TARDBP in vitro, researchers aim to uncover the molecular underpinnings of ALS and FTD, paving the way for potential therapeutic interventions targeting the misfolding and aggregation processes associated with these debilitating diseases. Overall, the investigation of recombinant TARDBP plays a pivotal role in advancing our understanding of its biology and the pathogenesis of related neurodegenerative disorders.
